March 1, 2019 Portfolio News from ARCH Venture Partners | Share Maze Therapeutics Launches to Focus on Translating Genetic Insights into New Medicines
February 7, 2019 Portfolio News from ARCH Venture Partners | Share New York Biotech Raises $61 Million To Keep Cancer Cells Dormant, Bucking Conventional Treatments
February 7, 2019 Portfolio News from ARCH Venture Partners | Share Gossamer Bio pulls off $276M IPO to push a trio of programs through the clinic
January 4, 2019 Portfolio News from ARCH Venture Partners | Share Sana Biotechnology Launches Focusing on Engineering Cells to Create a New Class of Medicines
December 27, 2018 Media Coverage from ARCH Venture Partners | Share Forbes Identifies ARCH as a 2018 Top Healthcare Investor
November 19, 2018 Portfolio News from ARCH Venture Partners | Share Leaders of ARCH-backed Nebula Named to Forbes’ 30 Under 30
November 6, 2018 Portfolio News from ARCH Venture Partners | Share Twist Bioscience IPO Hauls In $70M for DNA Synthesis Technology
October 17, 2018 Portfolio News from ARCH Venture Partners | Share Eyeing NASH, Glympse Raises $22M to Test Disease Detection Nanotech
July 20, 2018 Portfolio News from ARCH Venture Partners | Share Rubius Therapeutics Announces Pricing of Initial Public Offering
May 24, 2018 Portfolio News from ARCH Venture Partners | Share Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients
May 21, 2018 Portfolio News from ARCH Venture Partners | Share GRAIL Announces $300 Million Raised in Oversubscribed Series C Financing
